fr

EN DE

fr

EN DE

Publications

2027 PUBLICATIONS - effacer la recherche

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

2019

Cell death & disease

Dumont A

Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment.

2019

Cancers

Elmallah MIY

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy.

2019

Cancer epidemiology

Drouillard A

Net survival in recurrence-free colon cancer patients.

2019

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Flippot R

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

2019

Biochemical pharmacology

Zeniou M

Therapeutic considerations of PARP in stem cell biology: relevance in cancer and beyond.

2019

Revue des maladies respiratoires

Debieuvre D

[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].

2019

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Vendrely V

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).

2019

Cancers

Job S

Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on -Driven Oncogenic Addiction.

2019

European journal of cancer (Oxford, England : 1990)

Couraud S

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Eberst G

Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.